-
Gender Differences in the Economic Burden of Alcohol Use in Belgium
Sep 9, 2025, 16:22 PM -
Shifts in the French HTA Transparency Committee’s Use of Indirect Comparisons: Insights From a Systematic Review of the French Transparency Committee (TC) Opinions
Sep 9, 2025, 16:22 PM -
Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study
Sep 9, 2025, 16:22 PM -
Are Anti-Obesity Drugs Life-Saving or Lifestyle Medicines? Reframing the Policy and Economic Debate
Sep 9, 2025, 16:22 PM -
Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life of Caregivers of Children and Adolescents With Disease in Korea
Sep 9, 2025, 16:22 PM -
Characterizing the UK Population Living With Von Willebrand Disease: Foundational Data for Health Economics and Outcomes Research
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of High-Dose vs. Adjuvanted Trivalent Influenza Vaccines in Older Adults in Korea
Sep 9, 2025, 16:22 PM -
Costing Analysis for the Management of Localized Renal Cell Carcinoma From the UK NHS Perspective
Sep 9, 2025, 16:22 PM -
Clinical Relevance of a Machine Learning Model for Automated Analyses of Depression Severity: The ePHQ-9 in Treatment-Resistant Depression
Sep 9, 2025, 16:22 PM -
Uncovering the Cost Landscape of Congenital Heart Disease (CHD) With a Life Course Perspective: A Systematic Review of Healthcare Utilization by Lesion Type and Age
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 1 Diabetes in Sweden: A National Real-World Evidence Perspective
Sep 9, 2025, 16:22 PM -
A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain
Sep 9, 2025, 16:22 PM -
A Case Study: How England Implemented Its First Population Health Agreement
Sep 9, 2025, 16:22 PM -
Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases
Sep 9, 2025, 16:22 PM -
Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nirogacestat in Patients With Desmoid Tumors
Sep 9, 2025, 16:22 PM -
The Phantom Menace: How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access
Sep 9, 2025, 16:22 PM -
A Cross-Sectional Analysis of Early Access Programs in NICE Health Technology Assessments
Sep 9, 2025, 16:22 PM -
Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis
Sep 9, 2025, 16:22 PM -
Characterization of the Distribution of Body Mass Index in Portuguese People With Type 2 Diabetes
Sep 9, 2025, 16:22 PM
